01—History
Free Cash Flow History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2026. Drag across the bars to change the range.
- $875.8M
3 older moves run past ±150% (largest −401.8%); point at, tap or drag across the bars to read one.
02—Ledger
Free Cash Flow, period by period
| Period | Scale | Value | Change | Source |
|---|---|---|---|---|
| FY2026 | $875.8M | +30.4% | 10-K | |
| FY2025 | $671.5M | +129.3% | 10-K | |
| FY2023 | $292.9M | −12.6% | 10-K | |
| FY2022 | $334.9M | −3.4% | 10-K | |
| FY2021 | $346.6M | −32.6% | 10-K | |
| FY2020 | $514.1M | +34.4% | 10-K | |
| FY2018 | $382.4M | +164.7% | 10-K | |
| FY2017 | $144.5M | −30.8% | 10-K | |
| FY2016 | $208.7M | +246.9% | 10-K | |
| FY2015 | −$142.0M | +39.8% | 10-K | |
| FY2014 | −$235.9M | −17.4% | 10-K | |
| FY2013 | −$200.9M | −59.7% | 10-K | |
| FY2012 | −$125.9M | +21.4% | 10-K | |
| FY2011 | −$160.2M | −55.8% | 10-K | |
| FY2010 | −$102.9M | −401.8% | 10-K | |
| FY2009 | −$20.5M | — | 10-K |
03—Questions
What is Exelixis's current free cash flow?
Exelixis (EXEL) annual free cash flow for 2026 was $875.8M, a 30.42% increase from 2025. Exelixis free cash flow for the quarter ending October 2, 2026 was $277.5M.
What was Exelixis's free cash flow in 2025?
Exelixis annual free cash flow for 2025 was $671.5M, a 129.31% increase from 2023.
What was Exelixis's free cash flow in 2023?
Exelixis annual free cash flow for 2023 was $292.9M, a 12.56% decline from 2022.
What is Exelixis's 5-year free cash flow CAGR?
Exelixis free cash flow grew at a compound annual growth rate (CAGR) of 20.37% from FY2021 to FY2026, going from $346.6M to $875.8M over 5 years.
- Company
- Exelixis
- Ticker
- EXEL
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)